CGTXCOGNITION THERAPEUTICS INC

Nasdaq cogrx.com


$ 0.75 $ 0.05 (6.76 %)    

Monday, 19-Aug-2024 15:29:21 EDT
QQQ $ 481.94 $ 0.64 (0.13 %)
DIA $ 408.85 $ -0.04 (-0.01 %)
SPY $ 560.16 $ 1.00 (0.18 %)
TLT $ 98.32 $ 0.02 (0.02 %)
GLD $ 233.73 $ 0.01 (0 %)
$ 0.758
$ 0.70 x 200
-- x --
-- - --
$ 0.54 - $ 2.95
443,157
na
30.37M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-17-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-cognition-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the ...

 cognition-therapeutics-q2-2024-gaap-eps-018-beats-024-estimate

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate o...

 b-riley-securities-downgrades-cognition-therapeutics-to-neutral-lowers-price-target-to-1

B. Riley Securities analyst Mayank Mamtani downgrades Cognition Therapeutics (NASDAQ:CGTX) from Buy to Neutral and lowers th...

 hc-wainwright--co-maintains-buy-on-cognition-therapeutics-lowers-price-target-to-7

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the ...

 cantor-fitzgerald-downgrades-cognition-therapeutics-to-neutral

Cantor Fitzgerald analyst Charles Duncan downgrades Cognition Therapeutics (NASDAQ:CGTX) from Overweight to Neutral.

 cognition-therapeutics-stock-tumbles-on-mixed-data-from-mid-stage-alzheimers-study

Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patien...

 cognition-therapeutics-reports-phase-2-results-for-alzheimers-drug

Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing ...

 cognition-therapeutics-hosts-investor-webcast-to-discuss-results-from-phase-2-shine-study-of-ct1812-in-mild-to-moderate-alzheimers-disease-at-830am-et-on-monday-july-29-2024

Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing ...

 rodman--renshaw-reiterates-buy-on-cognition-therapeutics-maintains-14-price-target

Rodman & Renshaw analyst Elemer Piros reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $14 price...

 chardan-capital-initiates-coverage-on-cognition-therapeutics-with-buy-rating-announces-price-target-of-11

Chardan Capital analyst Daniil Gataulin initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rating and ann...

 hc-wainwright--co-initiates-coverage-on-cognition-therapeutics-with-buy-rating-announces-price-target-of-10

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION